BRIUMVI® (ublituximab-xiiy) IS NOW APPROVED. PRESCRIBING INFORMATION

FIERCELY FOCUSED
ON SOLUTIONS

THERAPEUTIC FOCUS

We are focused exclusively on diseases known to be caused by the abnormal behavior of B-cells, including all forms of B-cell non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and autoimmune disorders like multiple sclerosis (MS).

WHAT ARE B-CELLS?

B-cells belong to a family of white blood cells called lymphocytes. Lymphocytes include B-cells, T cells, and NK cells. B-cells play a crucial role in the immune system by producing antibodies to fight infections. By far, diseases attributed to the abnormal growth or function of B-cells are among some of the most common.

WHAT ARE B-CELL DISEASES?

The constellation of diseases that arise from abnormally growing or behaving B-cells is substantial. One group of diseases related to abnormal B-cell growth is malignant lymphomas, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). There are over 80 types of NHL, approximately 40 to 50 of which are due to malignant B-cells. These diseases can include some of the slowest and fastest growing cancers known to medicine. Some of the more common B-cell malignancies include marginal zone lymphoma (MZL), follicular lymphoma (FL), small lymphocytic lymphoma (SLL), and CLL.

The other major group of diseases caused by abnormally functioning B-cells is autoimmune disorders. These diseases result from inappropriate production of antibodies from the B-cells. These antibodies cannot discriminate “self” from “non-self,” and inadvertently mount a disabling immune response against normal organs. Examples of common and very debilitating autoimmune disorders include multiple sclerosis (MS) and rheumatoid arthritis (RA).

Our current pivotal clinical programs are focused on the development of innovative treatments for patients suffering from MZL/FL, CLL, and MS.